Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Sarepta Therapeutics Inc is a biotechnology business based in the US. Sarepta Therapeutics shares (SRPT) are listed on the NASDAQ and all prices are listed in US Dollars. Sarepta Therapeutics employs 866 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$80.24|
|52-week range||$65.30 - $181.83|
|50-day moving average||$86.85|
|200-day moving average||$77.81|
|Wall St. target price||$122.12|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-8.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||-1.21%|
|1 month (2021-09-24)||-11.41%|
|3 months (2021-07-23)||20.14%|
|6 months (2021-04-23)||13.11%|
|1 year (2020-10-23)||-41.74%|
|2 years (2019-10-25)||-6.43%|
|3 years (2018-10-25)||125.49|
|5 years (2016-10-25)||73.19%|
Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$600.1 million|
|Gross profit TTM||$-245,526,000|
|Return on assets TTM||-13.67%|
|Return on equity TTM||-83.05%|
|Market capitalisation||$6.9 billion|
TTM: trailing 12 months
There are currently 5.0 million Sarepta Therapeutics shares held short by investors – that's known as Sarepta Therapeutics's "short interest". This figure is 10.9% down from 5.7 million last month.
There are a few different ways that this level of interest in shorting Sarepta Therapeutics shares can be evaluated.
Sarepta Therapeutics's "short interest ratio" (SIR) is the quantity of Sarepta Therapeutics shares currently shorted divided by the average quantity of Sarepta Therapeutics shares traded daily (recently around 816960.77795786). Sarepta Therapeutics's SIR currently stands at 6.17. In other words for every 100,000 Sarepta Therapeutics shares traded daily on the market, roughly 6170 shares are currently held short.
However Sarepta Therapeutics's short interest can also be evaluated against the total number of Sarepta Therapeutics shares, or, against the total number of tradable Sarepta Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sarepta Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Sarepta Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.074% of the tradable shares (for every 100,000 tradable Sarepta Therapeutics shares, roughly 74 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Sarepta Therapeutics.
Find out more about how you can short Sarepta Therapeutics stock.
We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months.
Sarepta Therapeutics's shares were split on a 1:6 basis on 11 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Sarepta Therapeutics shares which in turn could have impacted Sarepta Therapeutics's share price.
Over the last 12 months, Sarepta Therapeutics's shares have ranged in value from as little as $65.3 up to $181.83. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 1.4228. This would suggest that Sarepta Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Sarepta Therapeutics, Inc. , a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.